LAB - Standard BioTools Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
South San Francisco,
United States
Type: Equity
LAB price evolution
LAB
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $35.32 | $32.44 | $36.01 | $19.66 |
| Inventory | $42.64 | $42.62 | $40.36 | $20.53 |
| Total current assets | $453.61 | $480.03 | $547.57 | $158.22 |
| Long term investments | ||||
| Property, plant & equipment | $72.25 | $74.1 | $77.75 | $54.85 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $681.54 | $708.73 | $777.67 | $323.07 |
| Current liabilities | ||||
| Accounts payable | $10.93 | $12.57 | $13.14 | $9.24 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $120.61 | $123.81 | $121.55 | $109.33 |
| Long term debt | $0.3 | $0.3 | $0.3 | $3.98 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $192.21 | $198.47 | $200.35 | $159.87 |
| Shareholders' equity | ||||
| Retained earnings | -$1151.58 | -$1124.64 | -$1078.92 | -$1000.75 |
| Other shareholder equity | -$1.41 | $510.26 | -$1.79 | -$2.22 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $47.82 | |||
| Short term investments | ||||
| Net receivables | $19.66 | $17.28 | $18.32 | $25.42 |
| Inventory | $20.53 | $21.47 | $20.82 | $19.69 |
| Total current assets | $158.22 | $208.81 | $72.07 | $117.66 |
| Long term investments | ||||
| Property, plant & equipment | $54.85 | $59.53 | $65.15 | $55.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $323.07 | $390.31 | $275.21 | $324.76 |
| Current liabilities | ||||
| Accounts payable | $9.24 | $7.91 | $10.6 | $9.22 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $109.33 | $43.44 | $49.57 | $54.25 |
| Long term debt | $3.98 | $62.81 | $64.21 | $54.22 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $159.87 | $160.52 | $180.62 | $185.71 |
| Shareholders' equity | ||||
| Retained earnings | -$1000.75 | -$926.1 | -$736 | -$676.76 |
| Other shareholder equity | -$2.22 | -$81.47 | -$0.91 | $0.11 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $44.97 | $37.2 | $45.54 | $28.19 |
| Cost of revenue | ||||
| Gross Profit | $23.26 | $14.91 | $24.19 | $13.36 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $47.56 | $56.9 | $62.92 | $28.26 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.12 | $0.06 | $0.13 | -$0.16 |
| Interest expense | $3.94 | $4.44 | $5.17 | -$1.1 |
| Net income | ||||
| Net income | -$26.94 | -$45.72 | -$78.17 | -$19.78 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $106.34 | $97.9 | $130.58 | $138.14 |
| Cost of revenue | ||||
| Gross Profit | $50.45 | $37.1 | $69.37 | $83.33 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $113.49 | $153.3 | $136.83 | $134.36 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.45 | -$2.8 | -$4.42 | -$1.08 |
| Interest expense | -$4.57 | -$64.4 | -$3.82 | -$3.57 |
| Net income | ||||
| Net income | -$74.66 | -$190.1 | -$59.24 | -$53.02 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $337.45 | $368.33 | $318.07 | $20.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$48.1 | -$48.09 | -$19.73 | -$6.81 |
| Effect of exchange rate | -$0.52 | -$0.11 | -$0.02 | $0.03 |
| Change in cash and equivalents | $159.44 | $218.6 | $235.84 | -$29.83 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $20.24 | -$88.13 | -$11.95 | $39.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$6.81 | $230.76 | $15.96 | $20.86 |
| Effect of exchange rate | $0.03 | -$0.4 | -$0.02 | $0.39 |
| Change in cash and equivalents | -$29.83 | $52.86 | -$40.07 | $45.81 |
News
Fundamentals
| Market cap | $409.49M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 372.26M |
| Revenue | $155.90M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$170.60M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -2.40 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.63 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.46 |
|---|---|
| ROA | -27.40% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.76 |
| Quick ratio | 3.41 |